

Table 1. Coincidence of genes encoding calcineurin subunits and calcineurin-interacting proteins with locations of previously identified putative schizophrenia susceptibility loci

Gene name	Protein description	Gene location	Susceptibility loci	Refs.
Calcineurin subunits				
<i>PPP3R1</i>	Calcineurin B subunit	2p14	2p13–14	17, 21, 22
<i>PPP3CA</i>	Calcineurin A α subunit	4q24	4q22–26	16, 17, 23, 24
<i>PPP3CC</i>	Calcineurin A γ subunit	8p21.3	8p21–22	13–17
<i>PPP3CB</i>	Calcineurin A β subunit	10q22.3	10q22–3	25
Calcineurin binding proteins				
<i>CABIN</i> (= <i>CAIN</i>)	Calcineurin binding protein 1	22q11.23	22q11	2, 3
<i>CHP</i>	Calcium binding protein P22	15q15.1	15q15	26
<i>CS-1</i> (= <i>MYOZ2</i>)	Calcineurin binding protein calsarcin 1	4q26	4q25–26	16, 17, 23, 24
<i>CS-2</i> (= <i>MYOZ1</i>)	Calcineurin binding protein calsarcin 2	10q22.2	10q22–3	25
<i>CS-3</i> (= <i>MYOZ3</i>)	Calcineurin binding protein calsarcin 3	5q33.1	5q33.2	16
<i>AKAP5</i> (= <i>AKAP79</i>)	A kinase (PRKA) anchor protein 5	14q23.3	14q22–24	25, 27, 28
<i>FKBP5</i> (= <i>FKBP51</i>)	FK506 binding protein 5	6p21.31	6p21.3; 6p22–24	29–31
Proteins functionally coupled to calcineurin				
<i>ITPR1</i>	Inositol 1,4,5-triphosphate receptor, Type 1 (IP3 receptor 1)	3p26.1	3p24–26	13
<i>RYR3</i>	Ryanodine receptor type 3	15q13.3–15q14	15q14	3, 32
<i>ILF2</i> (= <i>NF45</i>)	Subunit of nuclear factor of activated T cells (NFAT)	1q21.3	1q21.3	33
<i>CAMLG</i>	Calcium modulating ligand	5q31.1	5q23.3–31.1	17, 34–36
<i>NFATC2</i>	Nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 2	20q13.2	20q13	32

Gene locations are according to the November 2002 human draft sequence.

Brain Expression. Adult total human brain, fetal total human brain, and human testis cDNA consisted of marathon-ready cDNAs purchased from CLONTECH. Primer pair one consists of a forward primer from *PPP3CC* exon 1, 5'-GCGCTTCCACCTCTCCACC-3' and a reverse primer from *PPP3CC* exon 2, 5'-CTATCATAGTCTTCTCTTGCCTC-3'. Primer pair 2 consists of a forward primer, 5'-CCCATTTCATGACTTA-GAGTCC-3' and a reverse primer, 5'-CCCCTTTATAGCA-CAAGACTTC-3' from *PPP3CC* exon 14 (3' UTR). These primers were designed to differ from *PPP3CA* and *PPP3CB* sequence, particularly at the 3' end, to be *PPP3CC* specific. The adult human brain region panel was purchased from Origene (Rockville, MD). Fragments were amplified in a 25- μ l reaction mixture containing $\approx$ 0.25 ng cDNA (CLONTECH) or 1.0 ng (Origene), each primer at 400 nM concentration, each dNTP at 200 μ M concentration and 1.5 units of Taq polymerase (Sigma) in OptiPrime (Stratagene) buffer 6 conditions. Reactions were performed by touchdown PCR amplification as follows: an initial denaturation step at 94°C for 2 min, followed by 20 amplification cycles: 30 sec at 94°C; 45 sec at 68°C initially, 45 sec at 72°C (minus 1°C at each cycle) followed by 15 amplification cycles: 30 sec at 94°C; 45 sec at 53°C, 45 sec at 72°C, followed by a final extension step at 72°C for 7 min. Products were subjected to 2% agarose gel electrophoresis, visualized by ethidium bromide staining and photographed by using an eagle eye apparatus (Stratagene).

Results

Collectively, the behavioral abnormalities observed in forebrain-specific CNB knockout mice (see accompanying article) suggest that calcineurin dysfunction could be involved in schizophrenia pathogenesis. To determine whether alterations in calcineurin-related candidate genes could contribute to schizophrenia susceptibility, we are undertaking a comprehensive approach including genomic sequencing analysis of these genes in DNA from schizophrenia patients to identify polymorphisms, and transmission disequilibrium studies to examine the association of these

genes with disease in a large sample of affected families. We prioritized examination of calcineurin subunit genes and genes encoding proteins that interact with calcineurin that map to putative schizophrenia susceptibility loci identified by linkage studies. The coincidence of candidate genes from the calcineurin pathway and susceptibility loci is outlined in Table 1 and includes loci with variable statistical support and among them two loci that found strong support in a multicenter study (6p) (31) and in a recent metaanalytical survey (8p) (37). We report here results from our analysis of four such genes: *PPP3R1*, *PPP3CA*, *PPP3CC*, and *FKBP-5* located at 2p14, 4q24, 8p21.3, and 6p21.31, respectively.

To identify potential functional polymorphisms in these four genes that could contribute to schizophrenia susceptibility, as well as polymorphisms that could be used for association studies, we determined the sequence of coding and noncoding exons, splice donor and acceptor sites, and some intronic and promoter regions of these genes in genomic DNA isolated from 12 independent schizophrenia patients (U.S. schizophrenia sample) (18, 19). The obtained sequences were compared with the human draft sequence to identify polymorphisms.

Nineteen polymorphisms were found in the *PPP3R1* gene, 12 were found in the *PPP3CA* gene, 16 were found in the *PPP3CC* gene, and 4 were found in the *FKBP-5* gene (see supporting information for sequences and locations of these polymorphisms). Among these identified polymorphisms, only one caused a coding sequence alteration. This polymorphism (CC-5, Fig. 1) is situated in exon 5 of the *PPP3CC* gene and results in a nonconservative change in the amino acid sequence of the encoded protein from a charged arginine residue at position 163 to a neutral glutamine residue. Further analysis found the CC-5 polymorphism in 3 of 210 tested patients and in 0 of 75 unaffected Caucasian controls from the Coriell Cell Repository. Assessment of the significance of this mutation will require examination of expanded samples.

To further investigate the involvement of these four genes in schizophrenia pathogenesis, we have undertaken linkage dis-




Fig. 1. *PPP3CC* gene locus. (A) The location of the *PPP3CC* gene in the 8p21.3 region is depicted in relation to relevant markers from linkage studies. D8S136 (13); D8S1771 (15, 16); D8S1752 (15); and D8S1715 and D8S133 (14). (B) An expanded view of the *PPP3CC* gene is presented, including the exon/intron structure and the locations of the SNPs used for our association studies and of the coding sequence mutation identified in exon 5. This mutation changes a G to an A at position 824 of the mRNA (GenBank accession no. NM.005605). Distances and positions in this figure are according to the November 2002 human draft sequence. (C) Haplotype distribution and transmission at the *PPP3CC* locus. Only four haplotypes with frequencies $\geq 5\%$ were observed in both U.S. and SA samples and are shown here. The most common *PPP3CC* haplotype is consistently overtransmitted in both samples. T/nT, transmitted/nontransmitted.

equilibrium (LD) studies in large family samples (triads) that test for preferential transmission of common ($>10\%$ frequency) variants and multivariant haplotypes from parents to affected individuals. For this study we used a subset of the polymorphisms that we identified by direct sequencing, supplemented with additional SNPs obtained from the NCBI or Celera databases. See supporting information for further details of the examined polymorphisms.

We initially examined each allele of each marker, or a combination of two adjacent markers, for evidence of transmission disequilibrium by using the TDT test as implemented in the program TRANSMIT (20), in a sample of 210 triads collected from the United States (U.S. sample). The results of the association screen are indicated in Table 2 along with the pairwise disequilibrium coefficients (D') (38) for all marker pairs within each gene calculated for the nontransmitted chromosomes (Table 3). Analysis of the transmission revealed nominally significant association between schizophrenia and a subset of *PPP3CC* SNPs and two-SNP haplotypes. No other significant associations were observed (Table 2).

To better characterize the nature of the *PPP3CC* locus variant contributing to schizophrenia susceptibility, we analyzed the U.S. sample for preferential transmission of specific haplotypes by using genotypes from all five *PPP3CC* SNPs. The *PPP3CC* locus shows limited haplotypic diversity over the tested region (62.8 kb), which is likely adequately captured by the SNPs genotyped here. Only four haplotypes with frequencies $\geq 5\%$ were observed, in agreement with the observed strong linkage disequilibrium among the tested SNPs. A nominally significant global transmission distortion ($P = 0.0038$) was observed that could be primarily accounted for by a significant overtransmission to affected probands of the most common *PPP3CC* haplotype. This risk haplotype is present in $\approx 38\%$ of the parental chromosomes and was overtransmitted at a ratio of T/nT: 1.23/1 ($P = 0.0022$). The allelic composition of this haplotype reflects the single-locus results.

Overall, our initial analysis provided evidence for a nominally significant association between the *PPP3CC* gene and

Table 2. TDT results in the U.S. sample

Gene	Distance, kb	SNP	P values	
			One SNP	Two SNP
<i>PPP3RI</i>	0.14	RIPI	0.381	
		RI51	0.649	0.810
		RI24	0.206	0.604
		RI28	0.297	0.603
		RI53	0.976	0.471
<i>PPP3CA</i>	0.14	CAS6	0.556	
		casFP1	0.470	0.710
		casFP2	0.221	0.296
<i>FKBP5</i>	0.14	CA31	0.745	0.216
		FK-S1	0.118	0.285
		FK-33	0.454	0.822
		FK-35	0.544	0.485
<i>PPP3CC</i>	1.7	FK-36	0.793	
		CC1a	0.777	0.752
		CC20	0.380	0.169
		CC21	0.038	0.013
		CC33	0.099	0.003
		CCS3	0.041	

Table 3. Pairwise disequilibrium values for the U.S. sample

Genes		Pairwise D' values			
<i>PPP3RI</i>					
RI51	RIPI	0.86			
RI24		0.96			
RI28		0.98			
RI53		1			
<i>PPP3CA</i>					
casFP1	CAS6	0.56	casFP1	casFP2	
casFP2		0.25	0.07		
CA31		0.25	0.40	0.97	
<i>FKBP5</i>					
FK-33	FK-S1	0.90	FK-33	FK-35	
FK-35		0.93	0.89		
FK-36		0.91	0.81	1	
<i>PPP3CC</i>					
CC20	CC1a	0.72	CC20	CC21	CC33
CC21		0.98	0.78		
CC33		0.89	0.39	0.67	
CCS3		0.97	0.51	0.90	0.91

Pairwise D' values are calculated on nontransmitted chromosomes.

schizophrenia in a U.S. sample and identified a common risk haplotype. We sought additional support for our findings by examining the pattern of the five-SNP haplotype transmissions in another family sample derived from an independently collected population consisting of 200 triads from the Tshwane (formerly known as Pretoria) and Cape Town area in South Africa (SA sample). It should be noted that previous linkage analysis in this founder population did not provide significant evidence for linkage at the 8p21 locus (D.H., J.A.G., G. Abecasis, and M.K., unpublished data), suggesting that the effect of a disease gene from this region would be, at best, small in this population. The frequency distribution of the multilocus haplotypes was almost identical in the two samples (heterogeneity χ^2 test, $P > 0.05$). Although no significant global transmission distortion was observed in the SA sample, a trend for overtransmission of the same common risk haplotype ($P = 0.07$) with an almost identical transmission distortion ratio (1.29/1) as well as an overall similar pattern of multiallelic transmissions, was clearly evident. As expected in the combined sample of 410 families, transmission of the CTGCA risk haplotype significantly deviated from random ($P = 0.00126$) with the haplotype overtransmitted 1.26 times to 1. Moreover, several two-, three-, and four-SNP haplotypes showed significant association with schizophrenia in the combined sample (Table 4). The most significant of these associations remains significant at the 0.01 level after adjusting for multiple testing, even with a Bonferroni correction (for the >40 nonindependent tests we performed).

One simple explanation for the observed pattern of association is that a putative causative variant(s) is present within the risk haplotype background. We have determined the sequence of all exons, all splice donor and acceptor sites, and 1,500 bp of promoter sequence from several patients that are homozygous for the risk haplotype and several that do not have the risk haplotype. This analysis did not identify any sequence alterations that segregate with the risk haplotype; therefore, it is likely that the putative causative variant(s) resides in an area of the *PPP3CC* locus that was not analyzed by sequencing. Because a potential causative variant linked to the risk haplotype is not present in the *PPP3CC* coding sequence, it is likely that the causative sequence variation affects *PPP3CC* transcript expression or processing. In this regard, studies to

Table 4. Haplotype transmission in the combined sample ($n = 410$ families)

		P values			
Gene	SNP	Two SNP	Three SNP	Four SNP	Five SNP
<i>PPP3CC</i>	CC1a				
		0.587			
	CC20		0.169		
		0.054		0.005	
	CC21		0.0008		0.00126
		0.0013		0.0001	
	CC33		0.0003		
		0.0004			
	CCS3				

P values represent global significance calculated from the global χ^2 values from TRANSMIT program TDT analysis.

determine whether the risk haplotype correlates with altered *PPP3CC* transcript expression or processing are of considerable interest.

PPP3CC has been designated a testis-specific calcineurin catalytic subunit gene based primarily on its initial characterization in the mouse (39). To determine whether *PPP3CC* is expressed in the human brain, we first performed PCR amplification of cDNA from human total adult brain and from total fetal brain with *PPP3CC*-specific primers. As shown in Fig. 2A, PCRs with two different primer pairs indicate that *PPP3CC* is expressed in the human adult and fetal brain. To further analyze the expression of *PPP3CC* in the human brain, we performed PCR amplification of a panel of CNS region-specific cDNAs with one of the *PPP3CC*-specific primer pairs. As shown in Fig. 2B, *PPP3CC* expression is detected in multiple regions of adult human brain including frontal and temporal lobes, hippocampus, amygdala, thalamus, striatum, substantia nigra, hypothalamus,




Fig. 2. *PPP3CC* expression in human brain. (A) PCR amplification of cDNA from human adult total brain, fetal total brain, and testis. PCR was performed on ≈ 0.25 ng of cDNA with two primer pairs. Primer pair 1 amplifies a 218-bp fragment extending from exon 1 to exon 2. Primer pair 2 amplifies a 298-bp fragment from exon 14 consisting of 3' UTR sequence. Lane 1, 100-bp marker; lane 2, adult brain, primer pair 1; lane 3, adult brain, primer pair 2; lane 4, fetal brain, primer pair 1; lane 5, fetal brain, primer pair 2; lane 6, testis, primer pair 1; lane 7, testis, primer pair 2; lane 8, no DNA control, primer pair 1; lane 9, no DNA control, primer pair 2. The products <100 bp in size are present in lanes 8 and 9 and are most likely primer-related amplification artifacts. (B) PCR amplification of cDNA from human adult brain regions. PCR was performed on ≈ 1.0 ng of cDNA with primer pair 1. Lane 1, 100-bp marker; lane 2, frontal lobe; lane 3, temporal lobe; lane 4, cerebellum; lane 5, hippocampus; lane 6, substantia nigra; lane 7, caudate nucleus; lane 8, amygdala; lane 9, thalamus; lane 10, hypothalamus; lane 11, pons; lane 12, medulla; lane 13, spinal cord.

cerebellum, pons, and medulla. *PPP3CC* expression is also detected in spinal cord.

Discussion

The spectrum of behavioral abnormalities observed in forebrain-specific CNB knockout mice (12) prompted us to employ transmission studies to directly test for genetic association of genes encoding calcineurin-related molecules with schizophrenia. In our initial analysis of four such genes, we have found evidence for a nominally significant over-transmission of a common *PPP3CC* gene haplotype (found in $\approx 40\%$ of human chromosomes) in a sample of 410 affected families. Our findings identify *PPP3CC* as a potential schizophrenia susceptibility gene and support the proposal that alterations in calcineurin signaling contribute to schizophrenia pathogenesis. The increase in disease risk associated with the risk haplotype is expected to be low ($\approx 30\%$). However, because of its high frequency, the risk haplotype may correspond to a high population attributable risk affecting a large percentage of schizophrenics.

The *PPP3CC* gene is located within chromosome 8p21.3, a region that has been identified as a schizophrenia susceptibility locus by linkage studies in several independent samples derived from different populations (Fig. 1) (13–16), as well as by a recent metaanalysis of whole-genome linkage scans (37). Because the purpose of our analysis was to test the contribution of candidate genes from the calcineurin pathway, we did not employ finer mapping techniques by using a denser collection of markers at the 8p21.3 locus. Therefore, we cannot formally exclude the possibility that the observed association signal originates from genes in the vicinity of the *PPP3CC* locus. Such genes include *SCAM-1* (src homology 3-containing adaptor protein 1), *PDLIM2*, and *EGR3/PILOT*, whose expression is modulated by neuronal activity (40), neuregulin signaling (41), and calcineurin activity (42). Nevertheless, it will be of interest to determine whether alterations in the *PPP3CC* gene account for the linkage results obtained for this region in these samples. Recently, the neuregulin (*NRG1*) gene, located at 8p12, has been identified as a potential schizophrenia susceptibility gene from the 8p locus, in Icelandic (43) and Scottish (44) populations. Markers representing the risk haplotype at the 5' end of the *NRG1* gene, that was found to be over-represented in Icelandic and Scottish patients, were genotyped for the identical samples used in the present study (D.H., J.A.G., and M.K., unpublished data). This analysis revealed a pattern of association directly opposite to the one observed for the *PPP3CC* gene with evidence for association in the SA sample and no evidence for association in the more diverse U.S. sample. This is consistent with the notion that more than one gene from the extended 8p region may be contributing to schizophrenia susceptibility, as already noted by others (37).

Our initial association analysis of four calcineurin-related genes has detected significant association for only the *PPP3CC* gene that needs to be replicated in additional samples. It remains possible that the other three genes confer a smaller disease risk in the U.S. population that is difficult to reveal by an association analysis with the number of SNPs per gene and the sample size used thus far. In this regard, examination of these genes in expanded samples and in different populations remains of interest. In particular, examination of potential association of *PPP3R1* with schizophrenia in the Palauan population will be informative, because a 2p13–14 susceptibility locus was identified by linkage studies in this population (21, 22). In addition to the four genes examined here, other calcineurin-related genes map to putative schizophrenia susceptibility loci (Table 1). Further examination of members of this group of genes in relation to schizophrenia is required.

There are several possible mechanisms by which altered calcineurin function could contribute to schizophrenia pathogenesis. Calcium-dependent activation of calcineurin leads to dephosphorylation of DARPP-32, which is phosphorylated after dopamine D1 receptor activation, and of the related inhibitor of protein phosphatase-1, inhibitor-1 (10, 45). Normal calcineurin function may be required for calcium-dependent regulation of downstream events in the D1-mediated dopaminergic signaling cascade. In addition, calcineurin is required for certain types of *N*-methyl-D-aspartate receptor-dependent synaptic plasticity including long-term depression (LTD) (10, 11). Thus, altered calcineurin activity could affect the range of bidirectional synaptic modifiability (11). The involvement of calcineurin in dopaminergic and glutamatergic signaling events raises the possibility that calcineurin function is required as a critical link between these two neurotransmitter systems.

A complex of calcineurin and dynamin-1 has been shown to be involved in regulation of clathrin-mediated endocytosis (46). This process has been implicated in endocytosis of synaptic vesicles (46) and α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (47). Altered calcineurin activity might therefore result in abnormal calcium-dependent regulation of critical synaptic endocytotic events and consequent abnormal synaptic function.

An interaction of calcineurin with the ryanodine receptor type 3/inositol triphosphate receptor 1 (ITPR1) complex has been shown to regulate intracellular calcium release (48). Furthermore, calcineurin activity has been shown to be required for expression of the ITPR1 in neurons (49). Therefore, altered calcineurin activity could lead to abnormal neuronal calcium homeostasis. In addition to its role in regulation of intracellular calcium release, calcineurin has recently been shown to be involved in serotonin-dependent modulation of L-type calcium channel function (50), suggesting that altered calcineurin activity could also lead to abnormal serotonergic modulation of calcium entry.

Lastly, calcineurin is required for the nuclear factor of activated T cell (NFAT)-mediated transcriptional response (51). At least one isoform of NFAT is expressed in the mammalian brain (52). Calcineurin activity has been shown to be required for the expression of specific genes in neurons (49), consistent with the possibility that altered calcineurin activity could lead to changes in calcium-dependent neuronal transcription that could have profound effects on neuronal function.

Conclusions

We have obtained several converging lines of evidence suggesting that altered calcineurin signaling could be a contributing factor in schizophrenia pathogenesis. Further investigation of the neuronal functions of calcineurin and related proteins, and continued investigation of the association of calcineurin-related candidate genes with schizophrenia should help to elucidate the involvement of altered calcineurin signaling in this condition. Hopefully such research will reveal new possibilities for therapeutic intervention.

We thank Junne Kamihara and David Housman for helpful advice and suggestions, and Shu Huang and Celina Lafaille for excellent technical assistance. This work was supported by National Institutes of Health Grant P50-MH58880 and a gift from Otsuka Maryland Research Institute, Inc. (to S.T.) and a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (to T.M.), as well as National Institutes of Health Grant R01-MH61399 (to M.K.). J.A.G. is supported by grants from the McKnight Endowment Fund for Neuroscience, the EJLB Foundation, and the New York City Council Speaker's Fund.

1. Lewis, D. A. & Lieberman, J. A. (2000) *Neuron* **28**, 325–334.
2. Karayiorgou, M. & Gogos, J. A. (1997) *Neuron* **19**, 967–979.
3. Thaker, G. K. & Carpenter, W. T., Jr. (2001) *Nat. Med.* **7**, 667–671.
4. Seeman, P. (1987) *Synapse* **1**, 133–152.
5. Tsai, G. & Coyle, J. T. (2002) *Annu. Rev. Pharmacol. Toxicol.* **42**, 165–179.
6. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M. & Carlsson, M. L. (2001) *Annu. Rev. Pharmacol. Toxicol.* **41**, 237–260.
7. Klee, C. B., Ren, H. & Wang, X. (1998) *J. Biol. Chem.* **273**, 13367–13370.
8. Shibasaki, F., Hallin, U. & Uchino, H. (2002) *J. Biochem. (Tokyo)* **131**, 1–15.
9. Greengard, P. (2001) *Science* **294**, 1024–1030.
10. Mulkey, R. M., Endo, S., Shenolikar, S. & Malenka, R. C. (1994) *Nature* **369**, 486–488.
11. Zeng, H., Chattarji, S., Barbarosie, M., Rondi-Reig, L., Philpot, B. D., Miyakawa, T., Bear, M. F. & Tonegawa, S. (2001) *Cell* **107**, 617–629.
12. Miyakawa, T., Leiter, L. M., Gerber, D. J., Gainetdinov, R. R., Sotnikova, T. D., Zeng, H., Caron, M. G. & Tonegawa, S. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 8987–8992.
13. Pulver, A. E., Lasseter, V. K., Kasch, L., Wolyniec, P., Nestadt, G., Blouin, J. L., Kimberland, M., Babb, R., Vourlis, S., Chen, H., *et al.* (1995) *Am. J. Med. Genet.* **60**, 252–260.
14. Kendler, K. S., MacLean, C. J., O'Neill, F. A., Burke, J., Murphy, B., Duke, F., Shinkwin, R., Easter, S. M., Webb, B. T., Zhang, J., *et al.* (1996) *Am. J. Psychiatry* **153**, 1534–1540.
15. Blouin, J. L., Dombroski, B. A., Nath, S. K., Lasseter, V. K., Wolyniec, P. S., Nestadt, G., Thornquist, M., Ullrich, G., McGrath, J., Kasch, L., *et al.* (1998) *Nat. Genet.* **20**, 70–73.
16. Gurling, H. M., Kalsi, G., Brynjolfsson, J., Sigmundsson, T., Sherrington, R., Mankoo, B. S., Read, T., Murphy, P., Blaveri, E., McQuillin, A., *et al.* (2001) *Am. J. Hum. Genet.* **68**, 661–673.
17. Straub, R. E., MacLean, C. J., Ma, Y., Webb, B. T., Myakishev, M. V., Harris-Kerr, C., Wormley, B., Sadek, H., Kadambi, B., O'Neill, F. A., *et al.* (2002) *Mol. Psychiatry* **7**, 542–559.
18. Liu, H., Heath, S. C., Sobin, C., Roos, J. L., Galke, B. L., Blundell, M. L., Lenane, M., Robertson, B., Wijsman, E. M., Rapoport, J. L., *et al.* (2002) *Proc. Natl. Acad. Sci. USA* **99**, 3717–3722.
19. Liu, H., Abecasis, G. R., Heath, S. C., Knowles, A., Demars, S., Chen, Y. J., Roos, J. L., Rapoport, J. L., Gogos, J. A. & Karayiorgou, M. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 16859–16864.
20. Clayton, D. (1999) *Am. J. Hum. Genet.* **65**, 1170–1177.
21. Coon, H., Myles-Worsley, M., Tiobech, J., Hoff, M., Rosenthal, J., Bennett, P., Reimherr, F., Wender, P., Dale, P., Polloi, A. & Byerley, W. (1998) *Mol. Psychiatry* **3**, 521–527.
22. Camp, N. J., Neuhausen, S. L., Tiobech, J., Polloi, A., Coon, H. & Myles-Worsley, M. (2001) *Am. J. Hum. Genet.* **69**, 1278–1289.
23. Levinson, D. F., Mahtani, M. M., Nancarrow, D. J., Brown, D. M., Kruglyak, L., Kirby, A., Hayward, N. K., Crowe, R. R., Andreasen, N. C., Black, D. W., *et al.* (1998) *Am. J. Psychiatry* **155**, 741–750.
24. Kennedy, J. L., Basile, V. S. & Macciardi, F. M. (1999) *Am. J. Med. Genet.* **88**, 224–228.
25. Bailer, U., Leisch, F., Meszaros, K., Lenzinger, E., Willinger, U., Strobl, R., Gebhardt, C., Gerhard, E., Fuchs, K., Sieghart, W., *et al.* (2000) *Neuropsychobiology* **42**, 175–182.
26. Stober, G., Saar, K., Ruschendorf, F., Meyer, J., Nurnberg, G., Jatzke, S., Franzek, E., Reis, A., Lesch, K. P., Wienker, T. F. & Beckmann, H. (2000) *Am. J. Hum. Genet.* **67**, 1201–1207.
27. Faraone, S. V., Matise, T., Svrakic, D., Pepple, J., Malaspina, D., Suarez, B., Hampe, C., Zambuto, C. T., Schmitt, K., Meyer, J., *et al.* (1998) *Am. J. Med. Genet.* **81**, 290–295.
28. Craddock, N. & Lendon, C. (1999) *Am. J. Med. Genet.* **88**, 244–254.
29. Chowdari, K. V., Xu, K., Zhang, F., Ma, C., Li, T., Xie, B. Y., Wood, J., Trucco, M., Tsoi, W. F., Saha, N., *et al.* (2001) *Hum. Immunol.* **62**, 714–724.
30. Wright, P., Donaldson, P. T., Underhill, J. A., Choudhuri, K., Doherty, D. G. & Murray, R. M. (1996) *Am. J. Psychiatry* **153**, 1530–1533.
31. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8 (1996) *Am. J. Med. Genet.* **67**, 580–594.
32. Freedman, R., Leonard, S., Olincy, A., Kaufmann, C. A., Malaspina, D., Cloninger, C. R., Svrakic, D., Faraone, S. V. & Tsuang, M. T. (2001) *Am. J. Med. Genet.* **105**, 794–800.
33. Brzustowicz, L. M., Hodgkinson, K. A., Chow, E. W., Honer, W. G. & Bassett, A. S. (2000) *Science* **288**, 678–682.
34. Schwab, S. G., Eckstein, G. N., Hallmayer, J., Lerer, B., Albus, M., Borrmann, M., Lichtermann, D., Ertl, M. A., Maier, W. & Wildenauer, D. B. (1997) *Mol. Psychiatry* **2**, 156–160.
35. Crowe, R. R. & Vieland, V. (1999) *Am. J. Med. Genet.* **88**, 229–232.
36. Paunio, T., Ekelund, J., Varilo, T., Parker, A., Hovatta, I., Turunen, J. A., Rinard, K., Foti, A., Terwilliger, J. D., Juvonen, H., *et al.* (2001) *Hum. Mol. Genet.* **10**, 3037–3048.
37. Badner, J. A. & Gershon, E. S. (2002) *Mol. Psychiatry* **7**, 405–411.
38. Lewontin, R. C. (1988) *Genetics* **120**, 849–852.
39. Muramatsu, T., Giri, P. R., Higuchi, S. & Kincaid, R. L. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 529–533.
40. Yamagata, K., Kaufmann, W. E., Lanahan, A., Papapavlou, M., Barnes, C. A., Andreasson, K. I. & Worley, P. F. (1994) *Learn. Mem.* **1**, 140–152.
41. Hippenmeyer, S., Shneider, N. A., Birchmeier, C., Burden, S. J., Jessell, T. M. & Arber, S. (2002) *Neuron* **36**, 1035–1049.
42. Mittelstadt, P. R. & Ashwell, J. D. (1998) *Mol. Cell. Biol.* **18**, 3744–3751.
43. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T. T., *et al.* (2002) *Am. J. Hum. Genet.* **71**, 877–892.
44. Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., Gunnarsdottir, S., Walker, N., Petursson, H., Crombie, C., *et al.* (2003) *Am. J. Hum. Genet.* **72**, 83–87.
45. Greengard, P., Allen, P. B. & Nairn, A. C. (1999) *Neuron* **23**, 435–447.
46. Lai, M. M., Hong, J. J., Ruggiero, A. M., Burnett, P. E., Slepnev, V. I., De Camilli, P. & Snyder, S. H. (1999) *J. Biol. Chem.* **274**, 25963–25966.
47. Haucke, V. (2000) *Nat. Neurosci.* **3**, 1230–1232.
48. Cameron, A. M., Steiner, J. P., Roskams, A. J., Ali, S. M., Ronnett, G. V. & Snyder, S. H. (1995) *Cell* **83**, 463–472.
49. Genazzani, A. A., Carafoli, E. & Guerini, D. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 5797–5801.
50. Day, M., Olson, P. A., Platzer, J., Striessnig, J. & Surmeier, D. J. (2002) *J. Neurophysiol.* **87**, 2490–2504.
51. Crabtree, G. R. & Olson, E. N. (2002) *Cell* **109** (Suppl.), S67–S79.
52. Plyte, S., Boncristiano, M., Fattori, E., Galvagni, F., Paccani, S. R., Majolini, M. B., Oliviero, S., Ciliberto, G., Telford, J. L. & Baldari, C. T. (2001) *J. Biol. Chem.* **276**, 14350–14358.